Cefepime microbiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 19: Line 19:
*[[Streptococcus pyogenes]] (Lancefield’s Group A streptococci)  
*[[Streptococcus pyogenes]] (Lancefield’s Group A streptococci)  
*[[Streptococcus viridans|Viridans group streptococci]].
*[[Streptococcus viridans|Viridans group streptococci]].
The following in vitro data are available, but their clinical significance is unknown.
Cefepime has been shown to have in vitro activity against most isolates of the following
microorganisms; however, the safety and effectiveness of cefepime in treating clinical
infections due to these microorganisms have not been established in adequate and well-controlled trials.
*[[Staphylococcus epidermidis]] (methicillin-susceptible isolates only)
*[[Staphylococcus saprophyticus]]
*[[Streptococcus agalactiae]] (Lancefield’s Group B streptococci)
NOTE: Most isolates of enterococci, eg, [[Enterococcus faecalis]], and [[methicillin-resistant
staphylococci]] are resistant to cefepime.
Aerobic Gram-Negative Microorganisms:
*[[Acinetobacter calcoaceticus]] subsp. lwoffii
*[[Citrobacter diversus]]
*[[Citrobacter freundii]]
*[[Enterobacter agglomerans]]
*[[Haemophilus influenzae]] (including beta-lactamase producing isolates)
*[[Hafnia alvei]]
*[[Klebsiella oxytoca]]
*[[Moraxella catarrhalis]] (including beta-lactamase producing isolates)
*[[Morganella morganii]]
*[[Proteus vulgaris]]
*[[Providencia rettgeri]]
*[[Providencia stuartii]]
*[[Serratia marcescens]]

Revision as of 18:32, 18 December 2013

Microbiology

Cefepime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefepime has a broad spectrum of in vitro activity that encompasses a wide range of Gram-positive and Gram-negative bacteria. Cefepime has a low affinity for chromosomally-encoded beta-lactamases. Cefepime is highly resistant to hydrolysis by most beta-lactamases and exhibits rapid penetration into Gram-negative bacterial cells. Within bacterial cells, the molecular targets of cefepime are the penicillin binding proteins (PBP).

Susceptible organisms

Aerobic Gram-Negative Microorganisms:

Aerobic Gram-Positive Microorganisms:

The following in vitro data are available, but their clinical significance is unknown. Cefepime has been shown to have in vitro activity against most isolates of the following microorganisms; however, the safety and effectiveness of cefepime in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled trials.


NOTE: Most isolates of enterococci, eg, Enterococcus faecalis, and [[methicillin-resistant staphylococci]] are resistant to cefepime. Aerobic Gram-Negative Microorganisms: